Enrico Forlin

Enrico Forlin

Auto-generated profile, based on publicly available information

Enrico Forlin

M.B.N. Nanomaterialia S.p.A., Carbonera, Treviso, Italy

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
FVFederica Vurro
Federica Vurro
MGMarco Gerosa
Marco Gerosa
ABAlice Busato
Alice Busato
MMMatilde Muccilli
Matilde Muccilli
EMEmil Milan
Emil Milan
PMPasquina Marzola
Pasquina Marzola
This paper reports a comprehensive investigation of a magnetic nanoparticle (MNP), named M55, which belongs to a class of innovative doped ferrite nanomaterials, characterized by a self-limiting temperature. M55 is obtained from M48, an MNP previously described by our group, by implementing an additional purification step in the synthesis. M55, after citrate and glucose coating, is named G-M55. The present study aimed to demonstrate the properties of G-M55 as a diagnostic contrast agent for MRI and magnetic particle imaging (MPI), and as an antitumoral agent in magnetic fluid hyperthermia (MFH). Similar specific absorption rate values were obtained by standard MFH and by an MPI apparatus. This result is of interest in relation to the application of localized MFH by MPI apparatus. We demonstrated the biocompatibility of G-M55 in a triple-negative human breast cancer line (MDA-MB-231), and its efficacy as an MFH agent in the same cell line. We also demonstrated the efficacy of MFH treatment with G-M55 in an experimental model of breast cancer. Overall, our results pave the way for the clinical application of G-M55 as an MFH agent in breast cancer therapy, allowing not only efficient treatment by both standard MFH apparatus and MPI but also temperature monitoring.

28 August 2019 in Polymers
Verified
Journal Article
Open access
PDF file
EBElodie Bugnicourt
Elodie Bugnicourt
NBNicola Brzoska
Nicola Brzoska
EKEsra Kucukpinar
Esra Kucukpinar
SPSeverine Philippe
Severine Philippe
EFEnrico Forlin
Enrico Forlin
Markus SchmidMarkus Schmid
Markus Schmid
Studies on composition optimisation showed that the mixing of nanoclays to whey protein-isolate (WPI)-based coating formulations offers an effective strategy to reduce the oxygen permeability of coated polymer films. The scaling up of the various processing stages of these formulations was undertaken to prove their industrial feasibility. The aim was to investigate the effect of various preparation methods at different production scales (pilot- and semi-industrial scale) on the barrier performance and morphological properties of the applied nanocomposites. A nano-enhanced composition was converted into a so-called “ready-to-use” formulation by means of a solid-state pre-dispersion process using ball-milling. The process yielded a nearly dust-free, free-flowing powder containing agglomerated particles, which can easily be mixed with water. The preparation of a coating formulation using the ready-to-use granules and its upscaling for roll-to-roll converting at pilot- and semi-industrial scale was also successfully implemented. The effects of both the production at various scales and ultrasound treatment on the morphology and barrier performance of the nanocomposites were characterized by transmission electron microscopy, scanning electron microscopy, as well as oxygen permeability measurements. Results have shown that the addition of nanoclays to WPI-based coating formulations ultimately led to significantly reduced oxygen permeabilities to 0.59 cm3, 100 µm·m−2·d−1·bar−1 (barrier improvement factor, BIF of 5.4) and 0.62 cm3, 100 µm·m−2·d−1·bar−1 (BIF of 5.1) in cases of pilot- and semi-industrial-processed coatings, respectively, compared to a reference without nanoclay. In both cases, a similar degree of nanoparticle orientation was achieved. It was concluded that the solid state pre-dispersion of the nanoplatelets during the production of the ready-to-use formulation is the predominant process determining the ultimate degree of nanoparticle orientation and dispersion state.

1 March 2025 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
Alessandro NegriAlessandro Negri
Alessandro Negri
ACAnita Conti
Anita Conti
EMEmil Milan
Emil Milan
EFEnrico Forlin
Enrico Forlin
FGFilippo Gherlinzoni
Filippo Gherlinzoni
PMPasquina Marzola
Pasquina Marzola
Purpose: This study investigates the theranostic potential of doped ferrite nanoparticles (NPs) with self-regulating temperature (SRT) properties, termed M55, coated with glucose (GM55), chitosan (CM55), and poly-ethylene glycol (PM55). The NPs were assessed for their physicochemical attributes, magnetic fluid hyperthermia (MFH) efficacy, dual-imaging capabilities in Magnetic Resonance Imaging (MRI) and Magnetic Particle Imaging (MPI), cytocompatibility, and cellular uptake. Methods: Physicochemical characterization was conducted using Fourier-transform infrared spectroscopy (FTIR), dynamic light scattering (DLS), and zeta potential measurements. The biocompatibility and cellular uptake were evaluated in MDA-MB-231 breast cancer cells, and MFH performance was tested in vitro. Following intravenous administration, MRI and MPI functionalities were analyzed through phantom studies and in vivo murine models. Results: Coated M55 NPs displayed high colloidal stability in water and effective functionalization. The specific absorption rate (SAR) of 24.4 ± 1.4 W/g confirmed their suitability for MFH applications. In vitro assays indicated excellent biocompatibility and substantial cellular internalization, with GM55 showing the highest uptake and MFH efficiency, reducing cell viability to 50.62 ± 3.92% post two treatment cycles, compared to 67.71 ± 6.11% (CM55) and 71.39 ± 5.84% (PM55). MRI transverse relaxivity (r2) values were notably high across all coatings, enhancing imaging contrast. MPI analysis demonstrated superior cell labeling sensitivity, with GM55 achieving the most pronounced detection. In vivo imaging confirmed effective NPs accumulation in the liver, underscoring their utility as dual MRI/MPI contrast agents (CAs). Conclusion: Coated M55 NPs exhibit significant promise as multifunctional theranostic agents for cancer treatment. GM55, in particular, offers superior MFH efficacy and cellular uptake, while CM55 and PM55 may present unique advantages for alternative biomedical applications. The dual-imaging capabilities of these NPs provide a robust platform for real-time monitoring of distribution and therapeutic outcomes. Future investigations will focus on optimizing NPs formulations and expanding in vivo assessments to advance clinical translation.

1 January 2018 in Inorganica Chimica Acta
Verified
Journal Article
Closed access
EFEnrico Forlin
Enrico Forlin
ALArianna E. Lanza
Arianna E. Lanza
CNCorrado Di Nicola
Corrado Di Nicola
MMMagda Monari
Magda Monari
MGMassimo Gazzano
Massimo Gazzano
LPLuciano Pandolfo
Luciano Pandolfo